Yeah the exempt distribution $1.2m + Hepa $6m + $13m PP = $20.6m

Thought the $13m might be the Sheik, wasn't sure, coincidental if not, just wasn't sure.

Hopefully that's enough dough to get thru Covid P2 & P3, plus operations during that trials period. If the Covid trials go well, then we are probably "golden" ... unless we still find a way to turn chicken soup into chicken feathers. At the very least we will probably find a way to stretch it out until we are short on cash again.

Still kinda blows my mind that we so narrowly missed on BoM (ugh stroke), have a rare BTD, amazing early Covid study info, ... and yet  here we are languishing sideways in the market, unable to get a really sweet looking BoM2 going, and late getting a relatively brief/cheap Covid trial going amid a worldwide Covid catasrophe.

I mean, it's not like we have some of our own urgency, or the clock is ticking on patents, or just simply the fact that others might actually benefit greatly from testing the science, right?